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Invading pathogens have unique molecular signatures that are recognized by Toll-like receptors (TLRs) resulting in either
activation of antigen-presenting cells (APCs) and/or costimulation of T cells inducing both innate and adaptive immunity. TLRs
are also involved in T-cell development and can reprogram Treg cells to become helper cells. T cells consist of various subsets, that
is, Th1, Th2, Th17, T follicular helper (Tfh), cytotoxic T lymphocytes (CTLs), regulatory T cells (Treg) and these originate from
thymic progenitor thymocytes. T-cell receptor (TCR) activation in distinct T-cell subsets with diﬀerent TLRs results in diﬀering
outcomes, for example, activation of TLR4 expressed in T cells promotes suppressive function of regulatory T cells (Treg), while
activation of TLR6 expressed in T cells abrogates Treg function. The current state of knowledge of regarding TLR-mediated T-cell
development and diﬀerentiation is reviewed.
1.Introduction
Innate immunity protects the host from pathogenic infec-
tious agents. Every infectious microorganism possesses con-
served molecular structures, for example, lipopolysaccha-
ride, peptidoglycan, ﬂagellin, microbial nucleic acids and
these are collectively referred to as pathogen-associated
molecular patterns (PAMPs) [1]. PAMPs are recognized by
corresponding germline-encoded pattern recognition recep-
tor (PRR) expressed on innate immune cells of the host,
for example, dendritic cells (DCs), macrophages and neu-
trophils [2, 3]. This triggers various signal pathways to
produce inﬂammatory responses and adaptive immunity
[4, 5].
At least 5 classes of PRRs have been characterized:
Toll-like receptors (TLRs), retinoic-acid-inducible gene-I-
(RIG-I-) like receptors (RLRs), nucleotide-binding domain
and leucine-rich repeat containing gene family (alternatively
named NOD-like receptors, NLRs), C-type lectin receptors
(CLRs) and cytosolic DNA receptors (CDRs) [4, 6]. TLRs
are membrane-bound receptors that sense PAMPs on the cell
surface or in endosomes [7], while RLRs and NLRs recognize
microbialmoleculesinthehostcytosol[8].CLRsareprimar-
ily expressed in myeloid cells and recognize polysaccharide
structures of pathogens inducing immune responses [6, 9].
With the exception of TLR9, CDRs are a new family com-
posedofatleast6membersthatalsotriggerinnateimmunity
upon detecting cytosolic DNA [10, 11]. TLRs were initially
discovered in 1997 [12] and represent a canonical family of
PRRs that govern adaptive immune response by inducing
a Th1-skewed response, immunoglobulin G2c production
and antigen-speciﬁc cytotoxic T lymphocyte (CTL) response
[13–15].
UponrecognitionofforeignantigenforDCsviatheTLR-
PAMP interaction [4, 16], immature DCs resident in tissues
mature into professional antigen-presenting cells (APCs) to
induce eﬀector and memory T-cell responses in lymphoid
organs. Additionally, DCs are capable of inducing antigen-
speciﬁc T-cell tolerance immunosuppression (Figure 1)[ 16].
T cells are divided into diﬀerent subsets based on their
phenotypes, intracellular molecules expression, cytokine
production, the lengths of telomeres and state of immunity
[17]. The current knowledge of TLRs activation in relation
to T-cell activation and diﬀerentiation is presented here.2 Clinical and Developmental Immunology
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Figure 1: The eﬀects of TLR on T-cell activation. PAMPs from invading pathogens bind with TLRs expressed in DCs, which causes DC
activation. Activated DCs migrate to the draining lymph nodes where, in the presence of co-stimulatory signals and instructing cytokines,
they present the antigen epitope with MHC molecules to activate naive T cells. DCs also induce iTreg in the presence of TGF-β and IL-2.
These activated T cells move to the site of infection to ﬁght against the invading pathogen. Activation of TLRs in activated T cells induces
theirsurvivalandclonalexpansion.DirectengagementofTLRiniTregcellspromotestheirexpansionwithreducedsuppressivefunctionand
reprograms them to diﬀerentiate into T helper cells, which in turn provide help to eﬀector cells. When the infected pathogen is eliminated,
theclearanceofTLRligandsresultsinthesuppressivefunctionoftheexpandediTregcellsbeingrestored.Thisservestoregulatetheexpanded
eﬀector T-cell population.
2. T LymphocyteDevelopment and
Subsets Differentiation
2.1. T-Cell Development in Thymus (Figure 2). Thymic T-
cell progenitors are believed to come from circulating
hematopoietic stem cells originating from bone marrow. All
peripheral T cells are developed from these progenitor cells
[18–20]. The entry of T-lymphoid progenitor cells at an
early embryonic developmental stage before vascularization
of thymus, or at later embryonic and postnatal stages
after vascularization, initiates development of T cells in the
thymus [21, 22]. Thus, T progenitor cells can travel to
and reside in thymus via either a nonvascular route at
an early embryonic developmental stage or via a vascular
way at late embryonic and postnatal stages. Chemokines
such as C-C chemokine receptor type 7 (CCR7) and
CCR9 play a role in the prevascular colonization of T-
cell progenitors into the thymus primordium [23], while
the combination of P-selectin and P-selectin glycoprotein
ligand-1 is involved in postnatal thymus seeding [22]. These
cells initially express neither CD4 nor CD8 and are referred
to CD4/CD8 double-negative (DN) thymocytes [24]. Such
DN thymocytes migrate from the corticomedullary junction
to the subcapsular region of the cortex and sequentially
transform into DN1 (CD44+CD25−), DN2 (CD44+CD25+),
DN3 (CD44−CD25+) and DN4 (CD44−CD25−)[ 25–27]
cells with weak expression of CD4, CD8, CD25 and CD44.
These are the direct precursors of CD4/CD8 double-positive
(DP) thymocytes [28]. DP thymocytes develop in thymus
cortex from pre-DP where son of sevenless gene 1 (Sos1),
a guanine nucleotide exchange factor for Ras, plays a
pivotal role during this transition [29]. DP thymocytes
express TCRαβ on the cell surface and these interact with
self-peptide-MHC complexes presented by cortical thymic
epithelial cells (cTECs) for positive selection (i.e., survival)
or negative selection (clonal deletion, i.e. death). The process
is determined by avidity and aggregation of TCR with the
ligand interacting with one another [30]. Development of
single positive (SP) lineages of CD4+CD8− or CD4−CD8+
thymocytes is determined during positive selection [20]
and the properties of protein degradation and self-peptide
presentation of cTEC may play a role in SP lineages positive
selection [30, 31].
Positively selected thymocytes migrate to the medulla
via CCR7-mediated chemotaxis [30]. The medullary TECs
(mTEC) ectopically express multifarious “tissue-speciﬁc”
antigens(TSAs)/peripheraltissue-restrictedantigens(PTAs),
that is, promiscuous gene expression representing peripheral
tissues [32, 33]. This expression is partially controlled by
the transcription factor autoimmune regulator (AIRE) [34].
Antigens from either apoptotic mature mTECs or peripheral
tissues are taken up by thymic DCs and cross-presented to
developing thymocytes to induce negative selection of self-
reactive thymocytes establishing self-tolerance [30]. It is sug-
gestedthatcirculatingDCsbearingperipheraltissueantigens
are also recruited intrathymically for cross-presentation andClinical and Developmental Immunology 3
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Figure 2: T-cell development and diﬀerentiation. It is believed that thymic lymphoid progenitor cells are derived from circulating hematopoietic stem cells
originatingfromthebonemarrow.TheinitialCD4/CD8double-negative(DN)thymocytesmigratefromthecorticomedullaryjunctiontothesubcapsularregion
of the cortex and sequentially transform into DN1 (CD44+CD25−), DN2 (CD44+CD25+), DN3 (CD44−CD25+), DN4 (CD44−CD25−) and pre-DP cells, which
weakly express CD4, CD8, CD25 and CD44. Then CD4/CD8 double-positive (DP) thymocytes under the inﬂuence of a guanine nucleotide exchange factor for
Ras,Sos1developTCRαβsurfaceexpression.cTECspresentself-peptide-MHCcomplexestoTCRαβtoinduceclonaldeletionorthymocytesdevelopingintoCD4
orCD8SPcelllineage.nTregcelldevelopmentpossiblybeginsattheDPstage.Foxp3+ DPthymocyteswithafunctionalIL-7receptorandupregulatedexpression
of Bcl-2 protect themselves from being negative selected. Foxp3+ DP thymocytes with CD103 expression are possible precursors of Foxp3+ CD8+ SP cells and
ﬁnally diﬀerentiate into nTreg cells. SP cells move to the medulla through CCR7-mediated chemotaxis and interact with mTECs, which promiscuously express
multifarious“tissue-speciﬁc”antigens.TheseantigensaretakenupbyDCsandcross-presentedtodevelopingthymocytestoinducenegativeselectionestablishing
self-tolerance or nTreg lineage development. Circulating DCs bearing peripheral tissue antigens are also recruited intrathymically for cross-presentation. mTECs
are also able to serve as APCs to induce nTreg lineage development and negative selection. Hassall’s corpuscles are required to support nascent nTreg cell
development. Positively selected mature thymocytes migrate through perivascular space in the corticomedullary junction and medulla and become peripheral
naive T lymphocytes. When infection occurs, APCs process antigen and present epitope in combination with MHC molecules to TCR on the T-cell membrane in
thepresenceofco-stimulatorymoleculesandwiththehelpofspeciﬁccytokinestoinduceT-celldiﬀerentiation.IL-12andIFN-γ areessentialfor theinduction of
Th1 cell. IL-4 and IL-2 are required for naive CD4+ T-cell diﬀerentiation into IL-4-producing Th2 cells. TGF-β stimulates naive CD4+ Tc e l lt od i ﬀerentiate into
Th17 cells in the presence of IL-6 or induces iTreg cell in the presence of IL-2. Th17 cells can also be induced by an alternative pathway through the cooperation
of TGF-β and IL-21 without the participation of IL-6. Tfh cells are induced with the help of IL-6 (mice) or IL-12 (human) to produce IL-21, which backfeeds to
promoteTfhcelldiﬀerentiation.Asamajortranscriptionfactor,T-betalongwithSTAT4andSTAT1isessentialforTh1celldiﬀerentiation.ActivatedTh1cellcan
produce IFN-γ and IL-2 to help CD8+ eﬀector T-cell functioning. GATA3 is the Th2 master regulator. STAT6 and STAT5 are essential in Th2 cell diﬀerentiation
and expansion. STAT3 cooperates with STAT6 in promoting Th2 cell development. TCF-1 participates in GATA3 activation and promotes STAT6-independent
IL-4-producing Th2 cell diﬀerentiation. Th2 cells secrete IL-4, IL-5 and IL-13 to boost antibody production in B cells against extracellular parasites. Production
of IL-17 by Th17 cells is ROR-γta n dR O R - α d e p e n d e n t .S T A T 3i si n v o l v e di nT h 1 7c e l ld i ﬀerentiation, expansion and maintenance. Th17 cells participate
in the immune response against extracellular bacteria by production of IL-17. Treg cell development is controlled by Foxp3 that is required for Treg lineage
commitment, diﬀerentiation, expansion and function. STAT5 promotes Treg cell development by enhanced expression of Foxp3. Treg cells play a critical role
in maintaining homeostasis and immune tolerance by suppression of eﬀector cell in a cell-contact or cytokine-mediated pattern. Lineage commitment of Tfh
cell is controlled by Bcl-6, while Blimp-1 plays an inhibitory eﬀect on Tfh cell generation and function. STAT3 is necessary for Tfh cell development. Tfh cells
interact with B cells in germinal center to induce generation of long-lived plasma cells and memory B cells. Naive CD8+ T cell primed by signals from TCR
and co-stimulatory molecules diﬀerentiate into early eﬀector cell expressing transcription factor T-bet and cytotoxic cytokines, for example, IFN-γ,T N F - α to
acquire partial cytolytic abilities. The early eﬀector cell further diﬀerentiates into late eﬀector cell or memory cell, and this is determined by multiple factors such
as the strength of IL-2R and the presence of IL-12, the presence of distinct amounts of intracellular components such as proteasome, T-bet, CD8 and IL-7Rα,
or the potency of TCR signals. T-bet and Blimp-1 are responsible for IFN-γ expression and participate in the cytolytic gene expression, for example, Granyeme
B, Perforin to induce short-lived eﬀector CD8+ T cells. STAT5 plays a critical role in maintenance of phenotype of eﬀector CD8+ Tc e l l s .E o m e sa n dB c l - 6
expressions favor memory CD8+ T-cells diﬀerentiation. STAT5 activation also promotes memory CD8+ T-cell survival.4 Clinical and Developmental Immunology
therefore involved in clonal deletion [35]. Mature thymo-
cytes that have completed T-cell development emigrate from
thymus through perivascular space in the corticomedullary
junction and medulla [36] to peripheral lymphoid organs.
T-cell emigration is regulated by sphingosine-1-phosphate
receptor 1 [37, 38]. Diﬀerent subsets of T cells may have
diﬀerent aﬃnities for blood/lymphatic vessels and these
determine the routes of emigration [32]. A new subset phe-
notypically and functionally distinct from peripheral naive T
cell that emigrates from the thymus referred to recent thymic
emigrants (RTEs) requires further maturation in secondary
lymphoid organ to become functionally competent periph-
eral T cells [39].
Self-tolerance is induced in thymus either by nega-
tive selection or by natural regulatory T cells (nTreg)
development. Most of the nTreg cells are derived from
CD4+ SPthymocytesresidinginthemedullarycompartment
of the thymus [40, 41]. It is hypothesized that toler-
ance of uncommon self-antigens such as myosin usually
presents after muscle injury is preferentially recognized by
TCR and mediated by nTreg cells. By contrast, cells that
are involved in chronic engagement of TCR/CD28 signaling
by recognizing ubiquitous antigen, for example, albumin,
the 5th component of complement, insulin, are negatively
selected [40, 42, 43]. Decreased presentation of cognate
antigens on mTECs or DCs can induce nTreg cell develop-
ment [44]. Distinct APC subsets may preserve diﬀerent TCR
speciﬁcities and their ability to mediate negative selection
[40, 45–47]. It has been suggested that forkhead box P3
(Foxp3) negative nTreg cell precursors, induced by TCR
signaling, can use interleukin-2 (IL-2), IL-15, or IL-7 to
activate Foxp3 expression without the need for additional
TCR signals [40]. It is believed that nTreg cell development
begins early at the DP stage in pediatric thymus. Foxp3+ DP
thymocytes with a functional IL-7 receptor and upregulated
expression of Bcl-2 protect themselves from being negative
selected. Foxp3+ DP thymocytes that express CD103 are
possible precursor of Foxp3+ CD8+ SP cells [48]. Hassall’s
corpuscles, groups of epithelial cells in the thymic medulla,
may serve as specialized small niches required to support
nascent nTreg cell development [49].
2.2. Development of T-Cell Peripheral Tolerance (Figure 3). In
addition to the tolerance induced in thymus, autoreactive T
cells that have escaped from negative selection in thymus due
to low avidity of TCR to self-peptide-MHC complex [50]
or insuﬃciently expressed TSA in mTECs will be deleted
(cell death) or inactivated (anergy) in periphery, that is,
peripheral tolerance [42].
Lymph nodes are a primary location where peripheral
tolerance takes place. It has been demonstrated that lymph
node stromal cells (LNSCs), similar to mTECs in thymus,
are able to express a variety of TSAs to induce immune
tolerance of T cells [51]. The peripheral expression of TSAs
is either AIRE dependent [52, 53] or independent [54].
Another regulating factor, deformed epidermal autoregula-
toryfactor1(Deaf1)isalsoinvolvedinPTAsexpression[55].
Deaf1 variant isoforms inhibit the transcriptional activity of
canonical Deaf1 and this suppresses PTA expression [55].
Deaf1 transcript has been detected in every subset of LNSCs
[56]. All the subsets of LNSCs can express TSAs and present
TSAs to activate antigen-speciﬁc CD8+ T cells under both
steady-state and inﬂammatory conditions [56]. By contrast,
cross-presentation of TSAs produced from LNSCs by lymph
node resident DCs does not seem to play an important role
[57]. Although TSA proteins expressed by LNSCs might
be functional [51, 58], the expression of TSA protein by
LNSCs is diﬀerent from its expression in peripheral tissue.
This is evidenced by the fact that even the products from a
single type of diﬀerentiated peripheral cell can be produced
separately from distinct subsets of LNSCs, for example,
both the protein of mlana gene expression and tyrosinase
are products of terminally diﬀerentiated melanocytes, their
mRNA expression as PTAs in lymph node is segregated
in ﬁbroblastic reticular cells (FRCs) [56] and lymphatic
endothelial cells (LECs) [54], respectively. In addition to
TSAs expressed by LNSCs, lymph can also serve as a source
of self-antigens to induce peripheral tolerance in lymph
node [59]. Compared with plasma, lymph contains more
processed protein fragments and peptides from draining
organs or tissues [60] and thus a signiﬁcant pool of self-
antigen for the induction of peripheral tolerance [59].
LNSCs are reported capable of upregulating co-
stimulatory molecules to induce T-cell lineage deletion
rather than activation [56]. The role of LNSCs in the
induction of Treg cell is unknown [51]. It has been sug-
gested that autoimmunity is promoted by induction of self-
antigen speciﬁc eﬀector-memory T cells when their TCR is
continuously engaged at sites of high TSA expression under
conditions of tissue injury, infection and/or inﬂammation
[42]. Without inﬂammation, DCs resident in peripheral
lymphorganswouldinducetoleranceinnaiveTcellsbearing
TCR with high avidity for self-antigen and incomplete
maturation of DC also serves tolerance induction [42]. The
peripheral deletion of autoreactive T-cell lineage is mediated
by an apoptosis involving activation of Fas receptor by Fas
ligand and inactivation of survival protein B cell lymphoma
2 (Bcl-2) by its antagonist Bcl-2-interacting mediator of
cell death (Bim) [42, 61]. A nonapoptotic mechanism of
peripheral deletion was recently identiﬁed in which autore-
active CD8+ T cells actively invade hepatocytes in liver and
are degraded in the endosome/lysosome of the hepatocytes
[62]. This process is known as emperipolesis [63] and has
been described as early as the 1920s [64]. The invasion of
T cells into hepatocyte is dependent on T-cell activation,
ﬁlamentous actin reorganization, myosin light chain kinase,
as well as other kinases like PI3K. Inhibition of this suicide
emperipolesis by wortmannin, a kinase inhibitor capable
of inhibiting T-cell invasion into hepatocytes in vivo,i s
associated with accumulation of autoreactive CD8+ Tc e l l si n
the liver, and breach of tolerance results in the development
of autoimmune hepatitis [62]. By interrupting costimula-
tion, functional tolerance of T cell, that is, anergy can be
developed and maintained by counter-regulatory receptors
suchascytotoxicTlymphocyte-associatedantigen-4(CTLA-
4) that shares structural similarity with CD28 capable of
binding CD80 and CD86 and blocking CD28 costimulation
[42,65].Anothercounter-regulatorymolecule,programmedClinical and Developmental Immunology 5
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Figure 3: Peripheral T-cell tolerance in lymph node. All the subsets of LNSC can express PTA. AIRE and Deaf1 are involved in the regulation
of this expression. Both the LNSC and follicular DC in lymph node can serve as APC to present or cross-present self-epitopes to T cells.
Lymph contains abundant-processed protein fragments and peptides from draining organs or tissues and serves as a signiﬁcant pool of
self-antigen for the induction of peripheral tolerance. LNSC can upregulate co-stimulatory molecules to induce T-cell lineage deletion. The
autoreactiveT-celllineagedeletionismediatedbyapoptosismediatedbyFasorBimsignalswheninﬂammationisabsent.Theengagementof
Fas ligand with Fas on T-cell surface triggers the apoptosis of activated T cell through caspase-dependent pathway. T-cell stimulation causes
downregulation of Bcl-2 and a transient slight upregulation of Bim and this results in increased uncomplex Bim which is combined with
Bcl-2 in resting status. This then activates Bcl-2 homologous antagonist/killer (Bak) and Bcl-2–associated X protein (Bax). Consequently,
the integrity of mitochondria is damaged and this culminates in cell death. The tolerogenic DCs induce T-cell functional tolerance, that is,
anergy by upregulation of either CTLA-4 or PD-1 expression in T cells. Augmented expression of CTLA-4 can block co-stimulatory signals
bybindingtoCD80/86incompetitionwithCD28toinduceT-cellanergy. Inrecognitionofself-antigen,PD-L1ontolerogenicDCsinteracts
withPD-1onTcellstolimitT-cellactivityinperipheraltissuesandmaintainTcellinunresponsiveness.PD-1suppressesthePI3Kinduction
andAktactivation.ThisdisturbscellularglucosemetabolismandimpairsT-cellsurvival.PD-1activationalsoinhibitsthecell-survivalfactor
Bcl-xL production. CTLA-4 engagement blocks Akt phosphorylation by activation of protein phosphatase 2. Engagement of both PD-1 and
CTLA-4 can signiﬁcantly decrease gene transcriptions of T cell being activated.
cell death-1 (PD-1) is also crucial for the maintenance of
peripheral tolerance [65].
2.3. Development of Mucosal Tolerance. Mucosa discussed
here are those that line the gastrointestinal system and
the respiratory system including nasal passages. The largest
immune organ of the body is the gut-associated lymphoid
tissue (GALT) consisting of Peyer’s patches and isolated lym-
phoid follicles [66] located within the small intestine. Each
meter of human intestine has approximately 1012 lymphoid
cells [67]. GALT processesdietary antigens and is responsible
for immunotolerance toward intestinal commensal ﬂora.
Intestinal commensal microbiota is essential for adaptive
and innate immunity. In germ-free mice, the absence of
these bacteria results in impaired local and systemic immune
responses. This is evidenced by a reduced number and
smaller sized Peyer’s patches, a reduced number of mesen-
teric lymph nodes and diminished IgA and IgG production
[66, 68–70].
Metabolitesofintestinalmicrobiota,forexample,inmice
with dextran-sulfate-sodium- (DSS-) induced colitis, short-
chain fatty acids such as acetate, a fermented product of
Biﬁdobacterium when it acts on dietary ﬁber, interact with
G-protein-coupledreceptor43andstopthediﬀerentiationof
IL-17-producingcellsinthelaminapropria[71].Metabolites
from food and food proteins also determine susceptibility to
systemic infection, immunoreactivity and immune tolerance
[72–75]. A unique property of mucosa when exposed to
ingested antigens is suppression of immune responses to
subsequent parenteral challenges with the same antigen [76,
77]. This physiologically induced tolerance is referred to as
oral tolerance [66, 67, 78, 79]. Mucosal DCs can produce
TGF-β, IL-10 and induce CD103+ DCs to promote Tregs
induction [80, 81]. Resident lamina propria CD103+ DCs
canpromote Foxp3+ Treg cell diﬀerentiation and induce gut-
homing receptors, for example, CCR9 and α4β7 integrin
expression in T cells [82].
The orally ingested antigen can be taken up by a variety
of mechanisms. Microfold cells (M cells) are specialized
epithelial cells without microvilli and thick glycocalyx in
the small intestine overlying Peyer’s patches and lymphoid
follicles and are responsible for transcytosis [69]. These6 Clinical and Developmental Immunology
cells express TLR4, platelet-activating factor receptor, α5β1
integrin and galectin-9 on cell surfaces that enable M cells
to sense and transport intestinal antigens into intraepithelial
pockets to be processed by APCs [83]. Intestinal columnar
epithelial cells are also capable of transporting luminal
antigens through these PRRs[83]or the epithelial-associated
neonatal Fc receptor to secrete and combine IgG or IgG-
antigen complexes to cross mucosal epithelial cells [84]. DCs
by their cellular processes which traverse the epithelium
without disrupting tight junctions can sense luminal anti-
gens [85, 86].
A variety of regulatory mechanisms are involved in oral
tolerance. The amount of ingested antigen is a major factor
that determines the mechanism of oral tolerance. Generally,
low amounts of antigen result in Treg induction while
higher doses lead to immune cell anergy or clonal deletion
[67]. Activation of mesenteric lymph node CD103+ DCs
preferentially induces Foxp3+ Treg cells diﬀerentiation from
Foxp3− naive conventional CD4+ T cells in the presence
of TGF-β and the dietary vitamin A metabolite, retinoic
acid [81, 87]. CD103+ DCs express a retinal dehydrogenase,
aldehyde dehydrogenase family 1 subfamily A2 that can
convertretinalorvitaminAintoretinoicacid.Thisfacilitates
Foxp3+ iTreg cell induction [81]. Even in the absence
of thymus-derived nTregs, the development of antigen-
speciﬁcCD4+CD25+Foxp3+CD45RBlow cellsthat are anergic
and suppressive can occur [76]. Gut CD103+ DCs also
expresses indoleamine 2, 3-dioxygenase (IDO) involved in
the activation of Foxp3+ iTreg cells and hence oral tolerance
[88]. TGF-β can transform IDO− DCs into IDO+ DCs in
mice and prostaglandin E2 plays similar role in human [67].
This process involves intracellular signaling for the self-
ampliﬁcation and maintenance of a stable regulatory pheno-
type in pDCs [89].
All major types of regulatory T cells are involved in
oral tolerance, including thymic-derived nTreg, mucosally
induced iTreg, IL-10 secreting CD4+CD25lowCD45RBlow
typ e1r e g u l a t o ryTc e l l(T r 1c e l l ) ,T G F - β-dependent latency-
associated peptide (LAP)+ Th3 type Treg and CD8+ Treg
[67]. LAP is a propeptide capable of combining TGF-
β to constitute a latent TGF-β complex [90]. It has
been suggested that after exposure of oral antigen,
CD4+CD25−Foxp3−LAP+ Th3 cells produce TGF-β to sup-
port CD4+CD25+Foxp3+ nTreg cells, induce CD4+Foxp3−
T-cells diﬀerentiation into Foxp3+CD25+LAP−iTreg cells
and suppress Th1 and Th2 responses [67]. iTreg cells may
modulate DCs to produce IL-27 which induces IL-10-
producing Tr1 cells [91]. Foxp3+ iTreg cells are essential for
mucosal tolerance development [92]. Oral tolerance can also
be elicited by oral administration of anti-CD3 monoclonal
antibody instead of application of cognate antigen to activate
TCR and induce Th3 type CD4+CD25−LAP+ Tregs in
mesenteric lymph nodes [93]. Oral exposure to ligands of
aryl hydrocarbon receptor is also capable of inducing Foxp3+
Treg and Tr1 cells by acting on both T cells and DCs
producing IL-27, retinoic acid and IL-10 in the gut [94, 95].
NasaladministrationofantigenpreferentiallyinducesIL-
10-dependent Treg cell development, for example, Tr1 cell
and CD4+CD25−LAP+ Treg cell [67, 96, 97]. As the antigen
exposed to respiratory mucosa does not exert digestion that
occurred in the gut, the antigen dosage required to induce
nasal tolerance is smaller than that needed in the induction
of oral tolerance [98]. DCs that produce IL-10 in the lungs
are critical in the induction of IL-10-secreting Tr1 cell devel-
opment which elicits nasal tolerance [99]. The CD4+Foxp3+
Treg cells expressing membrane-bound TGF-β also partici-
pates in nasal tolerance [100]. CCR7-dependent migration
of CD103+ and CD103− pulmonary dendritic cells to the
bronchial lymph node is indispensable for nasal tolerance
induction [101]. CD11b+ and CD103+ DCs are the major
DC subsets in the lung. In contrast to the actions in the gut,
pulmonary CD103+ DCs appears to prime Th2 responses to
the inhaled antigen while CD11bhi DCs elicit Th1 responses
[102].
2.4.T-CellSubsetsDevelopmentandDiﬀerentiationinPeriph-
ery (Figure 2). CD4+ T cells play critical roles in the func-
tioning of the host immune system. Upon stimulation, pe-
ripheral CD4+ T cells can diﬀerentiate into T helper (Th)
cells or inducible Treg cells (iTreg). Currently, at least 4 Th
cell subsets have been identiﬁed, Th1, Th2, Th17 and iTreg
[103]. T follicular helper (Tfh) has been suggested as a new
subset of Th family [104–106]. There is debate whether new
s u b s e t ss u c ha sT h 9 ,T h 2 2[ 107–109] are separate lineages
[103, 110].
APCs take up antigen and digest it in the cytosol to pro-
cess the epitope. The epitope is then presented together with
MHC molecules to TCR on the T-cell surface. Simultane-
ously, APCs also secrete co-stimulatory molecules for exam-
ple, CD80, CD86 that bind the co-stimulatory receptor of T
cells, for example, CD28. Thus all 3 elements are required
for T-cell activation, that is, epitope, MHC molecules and
costimulation signals. Upon TCR activation, T cells produce
CD154 (alternatively named CD40L) to bind CD40 on the
cell surface of APCs to further activate APCs. The lineage
commitment of Th cells is determined by the cytokine
milieu, transcription factors and co-stimulatory molecules
such as CD28, CD154. The transcription factors involved in
this process are activated by TCR signaling [16, 103]. IL-
12 [111] and interferon (IFN) γ [112] are essential for the
inductionoftheTh1cells.Whencognateantigenstimulation
is present, IL-4 and IL-2 are required by the naive CD4+
Tc e l l st od i ﬀerentiate into IL-4-producing Th2 cells [113,
114]. Transforming growth factor- (TGF-) β stimulates naive
CD4+ T cells either to diﬀerentiate into Th17 cells in the
presence of IL-6 or alternatively diﬀerentiate into iTreg cells
in the presence of IL-2 (or IL-1β in human) [115–117]. In
the absence of IL-6 and in the presence of TGF-β and IL-21,
Th17cellscanalsobeinduced[118].PrimedCD4+ Tcellsare
also able to diﬀerentiate into Tfh cells in the presence of IL-6
(mice) or IL-12 (human) expressing IL-21 [119–122]. IL-21
c a np r o m o t eT f hc e l ld i ﬀerentiation by feedback. Therefore,
ithasbeenproposedthatmajorproductsofthediﬀerentiated
cells, for example, IFN-γ from Th1, IL-4 from Th2, IL-17
from Th17, IL-21 from Tfh, play critical roles in its self-
induction [103].
Newly primed CD4+ T cells are programmed by var-
ious cytokines and other factors from DCs to produceClinical and Developmental Immunology 7
transcription factors. T box expressed in T cells (T-bet) is
a major factor for Th1 cell diﬀerentiation and IFN-γ
production [123]. It can induce chromatin remodeling of
IFN-γ alleles and IL-12 receptor (IL-12R) β2 expression
a n dt h i sp r o m o t e sI F N - γ production as well as Th1 cell
expansion induced by IL-12 [124]. However, in mature Th1
cells, reiteration of IFN-γ expression and stable chromatin
remodelingarerelativelyindependentofT-betactivity[125].
Signal transducer and activator of transcription (STAT)
protein 4 and STAT1 are involved in Th1 cell diﬀerentiation.
STAT4 is activated by IL-12 leading to Th1 and Th17 cells
diﬀerentiation. IFN-γ production also occurs with nuclear
factor κB( N F - κB) with multiple cis elements being involved
[126, 127]. STAT1 can be activated by IFN-γ and serves
as a regulator of T-bet activation and subsequent IL-12R
expression in vitro [128]. The role of IFN-γ/STAT1 autocrine
pathway in CD4+ T-cell diﬀerentiation in vivo is not fully
understood [103].
GATA3, a member of GATA transcription factor family
capable of binding to the DNA sequence “GATA,” is the
master regulator of Th2 [129]. Without GATA3, Th2 cell dif-
ferentiation is completely abolished both in vivo and in vitro
[130,131].GATA3canbindto1279genesinTh2cellsand17
genes in 26 highly Th2-speciﬁc STAT6-dependent inducible
genes. Among the 26 Th2-speciﬁc genes, 10 showed GATA3-
dependent transcription while the remaining 16 genes were
STAT6 dependent [132]. Production of Th2 cytokines is
also promoted by GATA3 binding to promoters of IL-5
[133], IL-13 [134], and enhancers of IL-4 [135]. GATA3 has
the ability to instruct Th2 commitment, promote Th2 cell
expansion, suppress Th1 cell diﬀerentiation, thus facilitating
Th2 diﬀerentiation [103].
STAT6 and STAT5 are essential in Th2 cell diﬀerentiation
and expansion [136–139]. In vitro studies showed that
activation of STAT6 is necessary and suﬃcient for Th2
cell diﬀerentiation with expansion triggered by IL-4 [140].
However, Th2 lineage commitment can still be induced by
activation of GATA3 in a STAT6-independent mannerin vivo
[141]. Thus, it is possible that other transcription factors
beside STAT6 may be involved in GATA3 activation. A recent
report suggested that T-cell factor 1 (TCF-1) participated in
GATA3 activation and promoted STAT6-independent IL-4-
producing Th2 cell diﬀerentiation [142]. However, TCF-1
expression can be suppressed by IL-4 mediated by STAT6.
Thus, the ﬁne-tuning mechanism of Th cell polarization
has a multichannel pattern [143]. STAT6 is also involved in
the expression of Th2-speciﬁc cytokines, for example, IL-
24 is mediated by the coordinate action of STAT6 and c-
Jun transcription factors at the transcriptional level [144].
Recently, it was reported that STAT3 cooperates with STAT6
in promoting Th2 cell development [145]. A strong STAT5
signaling, correlated with higher expression of CD25, is
required for Th2 and iTreg cell diﬀerentiation. By contrast,
weak STAT5 signaling causes cell proliferation and survival
of Th1 and Th17 cells [103]. In vivo, promiscuous expression
of an activated form of STAT5 suppresses the production of
bothTh1andTh17cytokinesandpromotesthedevelopment
of Th2 lineage cells [137].
ThemasterregulatorofTh17cellisretinoicacidreceptor
related orphan receptor-γt( R O R - γt) [146, 147]. ROR-γt
deﬁciency results in signiﬁcant reduction in IL-17 produc-
tion. The residual IL-17 production in ROR-γt-deﬁcient
cells appears to be attributed to ROR-α. Dual deﬁciency of
ROR-γta n dR O R - α completely abolished IL-17 production
[147]. SR1001, a high-aﬃnity synthetic ligand binding to
the ligand-binding domains of both ROR-γta n dR O R - α that
induces a conformational change within the ligand-binding
domain, is capable of reducing aﬃnity for coactivators and
increasing aﬃnity for corepressors. This results in suppres-
sion of the receptors’ transcriptional activity. Blocking the
activities of ROR-γta n dR O R - α with SR1001 can inhibit
Th17celldiﬀerentiationandfunctionandsuppresscytokines
expression in mature Th17 cells [148]. STAT3 is involved
in Th17 cell diﬀerentiation, expansion and maintenance
[103, 149]. Stimulation of the common precursor cell of
Treg/Th17 by IL-6 activates STAT3 signaling and induces
IL-21 expression [150]. IL-21 induces Th17 diﬀerentiation,
suppresses Foxp3 expression and maintains a sustained
STAT3 activation in a self-service autocrine pattern, that is,
Th17 cells secrete IL-21, which in turn causes Th17 cells to
induce cell diﬀerentiation [151]. STAT3 can also be activated
by IL-23 and is responsible for the induction of ROR-γta n d
IL-23R allowing the persistence of Th17 cells [103, 150, 152].
Treg cell development is controlled by the transcription
factor Foxp3 [153, 154]. Mutation of Foxp3 gene results in
fatal autoimmune disorders in human, for example, immune
dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome or in mice, for example, lymphoprolif-
erative disorder and stable expression of Foxp3 is essential
for immune homeostasis [155, 156]. Foxp3 is required for
Treg lineage commitment, diﬀerentiation, expansion and
function [153, 154, 157]. Sustained expression of Foxp3 in
the mature Treg cell is essential to maintain the existing
phenotype status and to execute the immunosuppressive
functionofTregcell.ReducedorabolishedFoxp3production
in Treg cells results in acquisition of eﬀector T-cell properties
to produce inﬂammatory cytokines [158–160]. Foxp3 is
probably a major but not the master regulator of Treg
cell [161] and indeed, it is not necessary for Treg cell
development or functioning under certain conditions, for
example, the lineage commitment of Treg cells in murine
thymus does not require the expression of functional
Foxp3 protein [162]. Activated puriﬁed naive CD4+ Tc e l l s
transduced with a retroviral vector encoding Foxp3 and a
Thy1.1 reporter produce a >95% Foxp3+ cell population
but reproduce only a fraction of the Treg cell signature
transcript [163]. Instead, other transcriptional regulators,
for example, the combination of IL-2–STAT5 signaling and
TGF-β or CD103 responding to Foxp3 play complementary
and synergistic roles in controlling Treg cell signature gene
expression [161]. Cytokines such as IL-2, TGF-β induce
Foxp3 expression and also activate STAT5. The latter directly
binds the promoter and the ﬁrst intron of Foxp3 gene to
promote Treg cell development. The loss of STAT5 activa-
tion abolished Treg cell diﬀerentiation [164–168]. However,
Foxp3 can be induced in the absence of STAT5 in developing
thymocytes, and the maintenance of Foxp3 expression in8 Clinical and Developmental Immunology
Treg cells is STAT5 independent [158]. Perhaps cytokine-
induced STAT5 activation is not required in the development
of CD4+CD25+CD122+GITRhiFoxp3− Treg cell progenitor.
Nevertheless, activated STAT5 plays a critical role in convert-
ingTregcellprogenitorsintomatureTregcells[40,137,169].
Treg cell suppresses Th1 cell function through inhibition of
IFN-γ transcription during Th1 priming without disrupting
T-bet expression and Th1 programming. This suppression
is either IL-10 dependent or independent depending on the
target T-cell stage of activation and its tissue location [170].
Lineage commitment of Tfh cells is controlled by tran-
scriptional factor Bcl-6, identiﬁed by the transcriptional
proﬁles obtained from microarray analysis in Tfh cells
that was Bcl-6 upregulated [171]. Bcl-6-deﬁcient T cells
were unable to diﬀerentiate into Tfh cells and could not
sustain germinal center responses [172, 173]. Enhanced
expression of Bcl-6 in CD4+ T cells promoted expression
of Tfh cell signature molecules CXCR5, CXCR4, PD-1, and
downregulated IFN-γ and IL-17 production [172] inhibited
other Th lineage cell diﬀerentiation [173]. A transcrip-
tional repressor, B lymphocyte-induced maturation protein
1 (Blimp-1) inhibits Tfh cell generation and function,
indicating reciprocal regulation of Bcl-6 and Blimp-1 during
Tfh cell diﬀerentiation [174]. STAT3 is necessary for Tfh
cell development [104, 175]. Deletion of STAT3 in CD4+
thymocytes resulted in a greatly reduced number of diﬀer-
entiated Tfh cells after immunization. STAT3 deﬁciency in T
cells also led to defective germinal-center B cell generation
and antibodies production [104, 175]. Without STAT3, for
example, blockage by a STAT3 inhibitor, even after being
activated by IL-6, Tfh cells did not signal B cells [175, 176].
When exposed to foreign antigens, peripheral naive
CD8+ Tc e l l sd i ﬀerentiate into two reciprocal subsets: short-
lived eﬀector T cells, that is, CTLs and long-lived memory
T cells [177–179]. Memory T cells can be subdivided into
central (Tcm) or eﬀector memory T cells (Tem). Tcm cells
express high levels of CCR7 and CD62L and lack immediate
eﬀector function but eﬃciently stimulate DCs in secondary
lymphoid organs inducing a new wave of eﬀector cells when
secondary challenge occurs. Tem cells express low levels
of CCR7 and CD62L, migrate to the infection site and
produce cytokines and cytolytic molecules [177, 180]. Tem
cellspossessmostfeaturesofCTL.However,Temcellspersist
after the elimination of the invading pathogen [177]. A
new memory T-cell subset with stem-cell-like properties has
recently been identiﬁed and termed memory stem T cell
(Tscm). This cell is present in humans [181]a n dm i c e[ 182].
Phenotypically within the naive T-cell compartment, for
example, CD45RO−, CCR7+, CD45RA+, CD62L+, CD27+,
CD28+ andIL-7Rα+,humanTscmcellshighlyexpressCD95,
CXCR3,Bcl-2,theβ chainoftheIL-2andIL-15receptor(IL-
2Rβ) and lymphocyte function-associated antigen 1 (LFA-
1). These cells possess the characteristics of memory T cells
such as the ability to rapidly acquire eﬀector functions upon
antigen rechallenge. They also can secrete inﬂammatory
cytokines in response to α-CD3/CD2/CD28 stimulation.
Such Tscm cells represent the least diﬀerentiated T memory
cell subset [181]. Wnt/β-catenin signaling may play a role
in the induction of this subset [183] but there is conﬂicting
evidence [184].
IthasbeensuggestedthattheCD8+ eﬀectorandmemory
T cell develops from a single precursor cell when instructed
by distinct TCR signals, cytokines [185–189] and not by the
APCorwhenprimingofTcelltakesplace[188].NaiveCD8+
Tcellswhenprimed bysignals fromTCRandco-stimulatory
molecules diﬀerentiate into precursor cells or early eﬀector
cells expressing transcription factor T-bet and cytotoxic
cytokines, for example, IFN-γ, tumor necrosis factor (TNF)
α to acquire partial cytolytic abilities [177]. Whether the
precursor cell further diﬀerentiates into late eﬀector cell or
memory cell is determined by a variety of factors such
as the amount of IL-2R and IL-12 [190, 191], varying
amounts of intracellular components, for example, T-bet,
CD8, CD69, CD43, CD25, CD44, diﬀerent expression of
IFN-γ,G r a n z y m eB ,I L - 7 R α, and distinct granularity due
to asymmetric division [187, 192]. Point mutations in the
TCR β transmembrane domain block the development and
functionofCD8+ memoryTcells.YetprimaryeﬀectorCD8+
T-cell response is not aﬀected by this mutation. Mutant T
cells are unable to induce polarized TCR and intact NF-κB
signals in the immunological synapse (the interface between
an APC and a lymphocyte). Therefore, distinct TCR signals
trigger diﬀerent programs for CD8+ T-cell diﬀerentiation
toward either eﬀector or memory pathways [186].
Transcriptional factors, T-bet, eomesodermin (Eomes),
Bcl-6 and Blimp-1 are involved in CD8+ T-cell diﬀerentia-
tion. T-bet is the master regulator of CD8+ T cells [178].
Its expression is responsible for IFN-γ production and it
participates in the activation of cytolytic genes, for example,
Granyeme B, Perforin expression of CD8+ Tc e l l[ 193].
The presence of T-bet with a low level of IL-2 signaling
is suﬃcient to induce CD8+ T cells to develop eﬀector
functions but other factors may also participate in terminal
diﬀerentiation [194, 195]. Eomes, another member of the T-
box family of transcriptional factors, is a key transcriptional
factor for CD8+ T-cell diﬀerentiation [196]. T-bet and
Eomes cooperate redundantly to induce eﬀector CD8+ T-
cell diﬀerentiation and can also act reciprocally to induce
memory CD8+ T-cell development [197]. T-bet promotes
the diﬀerentiation of short-lived eﬀector CD8+ Tc e l l sa t
the expense of central memory cells and Eomes expression
favors memory CD8+ T-cells diﬀerentiation [198, 199].
The diﬀering quantities of T-bet in diverse T-cell lineages
may be attributed to the asymmetric degradation [192].
Proteasomes are unequally distributed during asymmetric
cell division and this is responsible for the imbalanced
degradation of T-bet in the daughter cells resulting in
diﬀering allocation of T-bet to various cell lines [192].
Bcl-6 and Blimp-1 are transcriptional repressors. Blimp-
1 expression is required for the terminal diﬀerentiation of
eﬀector CD8+ T cells, that is, the short-lived CD8+ CTLs
[200–202]. Bcl-6 probably works as a reciprocal regulator
of Blimp-1 in the process of CD8+ T-cell diﬀerentiation
[203].Ingeneral,lymphocyteswithhigherexpressionofBcl-
6 exhibit greater proliferative capacity, less secretory capacity
and promote memory T-cell development. Lymphocytes
with higher expression of Blimp-1 exhibit lower proliferativeClinical and Developmental Immunology 9
capacity and greater secretory capacity and they are more
conducive to CTL development [203]. Blimp-1 is also highly
expressed in exhausted CD8+ T cells [204]. T-bet can induce
Blimp-1 transcription via enhanced IL-2R signaling [194].
STAT5 plays a critical role in the maintenance of
phenotype of eﬀector CD8+ T cells. It is also required in the
induction of the anti-apoptotic molecule Bcl-2 expression by
IL-7 and IL-15 and the maintenance of Bcl-2 expression in
eﬀector CD8+ T cells [205]. Constitutive STAT5 activation
can promote eﬀector and memory CD8+ T-cell survival and
Bcl-2 expression [206].
3.TLRs Signaling
3.1. The TLR Family. Toll was initially identiﬁed as an essen-
tial protein that plays a central role in the establishment of
dorsoventral polarity in the embryo of Drosophila [207,
208]. Later, it was recognized as a key modulator for
the immune response against fungi in adult Drosophila
[209]. Toll-receptor homologues have also been found to
be capable of activating adaptive immune response through
NF-κB signal [12, 210]. As these receptors are evolution-
ally and functionally homologous with Drosophila Toll,
collectively they are referred to as Toll-like receptors [210,
211].
Thirteen TLRs have been currently identiﬁed, TLR1 to
TLR13,ofwhichTLR1toTLR9areconservedbothinhuman
and mice. TLR10 is not functional in mice while TLR11,
TLR12 and TLR13 are absent from human genome [212].
TLRs are type-1 transmembrane glycoproteins with a tri-
modular structure consisting of an N-terminal extracellular
ectodomain characterized by inclusion of 16–28 leucine-
rich repeats (LRRs), a transmembrane portion containing
a single α-helix and an intracellular cytoplasmic portion
with Toll/IL-1 receptor (TIR) domain [213, 214]. Each LRR
region is composed of 24 amino acids with the conserved
motif XLXXLXXLXLXXNXLXXLPXXXFX in sequence, an
α-helix and a β-sheet connected by a loop in conformation
[214, 215]. The LRRs of the ectodomain combine to display
horseshoe-like shape. However, the LRR regions of TLR1,
TLR2 and TLR4 do not have the typical conformation in
that the conserved asparagine ladder in the central region of
LRRsisabsent.Consequently,thisallowsthemtoadjusttheir
conformation to bind a variety of ligands and coreceptors
for signaling [215]. The TIR domain is composed of a ﬁve-
stranded β-sheet encircled by 5 α-helices. The B-B loop that
connects β-strand B with α-helix B in the TIR domain is
considered the essential structure for TIR dimerization and
subsequent recruitment of TIR domain-containing adaptors
[215].
TLRscanbeclassiﬁedascell-surfaceTLRsorintracellular
TLRs. The former group consists of TLR1, TLR2, TLR4,
TLR5, TLR6, TLR10, TLR11 and TLR12, and it is largely
expressed on the cell surface and recognizes molecules
mainly from microbial membrane, for example, lipid, li-
poprotein, or lipopeptide and protein. The latter group
is composed of TLR3, TLR7, TLR8, TLR9, and perhaps
TLR13 in mice localized in intracellular compartments
like endoplasmic reticulum (ER), endosomes, lysosomes,
and endolysosomes to detect microbial nucleic acids [212,
216]. The distinct ligand-sensing functions of the individual
TLRs may explain their diﬀerent localization. TLRs on
cell surfaces mainly recognize molecules on the surface
of the pathogenic microorganisms while those localized
intracellularly sense nucleic acids which are released by
intracellular degradation of the invading pathogen [217]. An
advantage of the intracellular localization of nucleic-acid-
sensing TLRs may be the avoidance of TLRs activation by the
host homogeneous nucleic acid. Such nucleic acids released
from the dying cells can be readily degraded by serum or
cytoplasmic nucleotidases before their arrival to the endo-
some.Asnucleicacid-sensingTLRsresideintracellularly,this
prevents the occurrence of autoimmunity. However, viral
n u c l e i ca c i di sp r o t e c t e db yt h ev i r a lc a p s i dp r o t e i n sa n di s
capable of staying in the endolysosome, being recognized
by nucleic-acid-sensing TLRs to trigger antiviral immunity
[217, 218].
3.2.TLRSignalingPathway. IntracellularTLRsarepresentin
the ER in resting cells and move to endosomes upon stimu-
lation of the cells (Figure 4). Their residence in ER is main-
tained by retention signals, for example, the cytoplasmic
and ectodomains of TLR9 [219], a 23-amino acid sequence
[Glu(727) to Asp(749)] present in the linker region between
the transmembrane domain and TIR domain of TLR3 and
the transmembrane region of TLR7 [220]. These TLRs can
only be activated after being transported to endolysosome
[217]. The traﬃcking of intracellular TLR9 from ER to
endolysosomes is through traditional secretory pathways,
and Golgi export is required for optimal TLR9 signaling
[218, 221, 222]. Traﬃcking of TLR9 and TLR7 involves
a cleavage by lysosomal cysteine proteases within their
ectodomains. Without proteolytic modiﬁcation, their asso-
ciation with myeloid diﬀerentiation protein 88 (MyD88) and
subsequent signaling is disabled although the capacity of
ligand-bindingispreserved[216,218,221].Proteolysisisnot
required for TLR3 signaling during its intracellular traﬃck-
ing.
Chaperone proteins are required for maintaining the
retention of these TLRs in ER in resting cells and their intra-
cellular traﬃcking. UNC93B1, a highly conserved multiple
membrane-spanning protein in ER, is involved in traﬃcking
of nucleotide-sensing TLRs (Figure 4)[ 223]. A point muta-
tion of UNC93B1 abolishes signaling of TLR3, 7, 9 and 13
as binding to their transmembrane domains is prevented
[224]. Association with UNC93B1 promotes TLR9 signaling
and represses TLR7-mediated response and mutation of the
N-terminal D34A amino acid that suppresses TLR7 sig-
naling enhances TLR7 traﬃcking and downregulates TLR9
traﬃcking in DCs. This suggests UNC93B1 favors DNA
sensing but not RNA sensing. TLR3 signaling is promoted
by overexpression of UNC93B1 and not aﬀected by the N-
terminal mutation [225]. However, a recessive N-ethyl-N-
nitrosourea-inducedmutation(tripleDor3dmutation)that
is a missense allele of UNC93B1 disrupts exogenous antigen
presentation and signaling via TLR3, TLR7 and TLR9 [226].
Therefore, UNC93B1 is essential for intracellular TLRs
signaling and determines the traﬃcking eﬃciency of each10 Clinical and Developmental Immunology
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Figure 4: Intracellular TLRs traﬃc. Intracellular TLRs are present in the ER in resting cells and migrate to endosomes upon stimulation.
Chaperone proteins, for example, UNC93B1 are required for their residence in ER and for their intracellular traﬃcking. When the ligands
are taken into the cell, TLRs exit the ER through Golgi complex by conventional secretory pathways and reach the endolysosome where they
interact with the ligands. TLR9 is cleaved by lysosomal cysteine proteases within their ectodomains in the endolysosome. TLR3 does not
appear to be required for proteolysis during intracellular traﬃcking.
individual TLR from ER to endolysosome to recognize the
ligand and trigger subsequent response [216].
Upon binding ligands, TLRs dimerize to form homod-
imer or heterodimer (e.g., TLR2/TLR1, TLR2/TLR6 and per-
haps TLR2/TLR10) and recruit adaptor molecules through
the interaction of their intracellular TIR domain and
the TIR domain of adaptor molecules [227]. Four adap-
tor molecules have been characterized. MyD88 [228]
and TIR domain-containing adaptor inducing interferon-
β (TRIF)/TIR domain containing adaptor molecule-1
(TICAM-1) [229, 230] are the two major adaptors for TLRs
signaling. The remaining two adaptors, that is, TIR domain-
containing adapter protein (TIRAP)/MyD88-adapter-like
(Mal) [231, 232] and TRIF-related adaptor molecule
(TRAM)[233], bridge the TIR domains between some TLRs
andMyD88orTRIF,respectively.MyD88isauniversaladap-
tor for all TLRs except for TLR3 and activates NF-κB signal
pathway to induce inﬂammatory cytokines. TLR3 and TLR4
use TRIF as their adaptor to activate interferon regulatory
factor 3 (IRF3) and NF-κB to promote the productions
of type-I IFN and inﬂammatory cytokines. TIRAP/Mal is
required for TLR4 and TLR2 signal transduction by bridging
the TIR domain of TLR4 or TLR2 and MyD88 [215, 234].
Similarly,TRAMalsoactsasabridgingadaptorforTLR4and
TRIF [215].
MyD88 is the essential adaptor for most TLRs. Upon lig-
and recognition, TLR recruits MyD88 to its cytoplasmic TIR
domain by association with the TIR domain of the adap-
tor molecule (Figure 5). MyD88 possesses an N-terminal
death domain (DD) that associates with DD of IL-1R-
associated kinase-4 (IRAK4) [235]. IRAK1 and IRAK2 are
phosphorylated by IRAK4 and then activate TNF recep-
tor associated factor-6 (TRAF6) [236, 237]. TRAF6 acts as
an E3 ubiquitin protein ligase to ubiquitinate itself and
NF-κB essential modulator (NEMO) by the formation of
polyubiquitinchains.BothTRAF6andNEMOareconnected
with IRAK1 by the chains. These chains also connect NEMO
with the transforming growth factor β-activated kinase-1-
(TAK1-) binding proteins (TABs) including TAB2, 3 and
4 which promote phosphorylation of TAK1-TAB1 resulting
in TAK1 activation [238–241]. The activated TAK1 induces
phosphorylation of IκB kinase-related kinase (IKK) β. This
causes IκB phosphorylation and its dissociation with NF-κB.
Consequently, the nuclear translocation of NF-κB is induced
and this culminates in the transcription of proinﬂammatory
cytokines, for example, TNF and IL-6. The TAK1/TABs
complex also phosphorylates and activates c-Jun N-terminal
kinase (JNK) and p38 resulting in activation of activator
protein 1 (AP1) [216, 227]. IRF5 can be activated by both
MyD88 and TRAF6, and it promotes the transcription of
proinﬂammatory cytokines [242]. This can be inhibited by
the competition by IRF4 [243]. TRAF6 also induces TRAF3
triggering noncanonical TRAF3 self-ubiquitination [244]
and this complex associates with TRAF family-member-
associated NF-κB activator-binding kinase 1 (TBK1). It then
acts with IRF3 to induce IFN-β production. Ubiquitinated
TRAF3 also induces the anti-inﬂammatory cytokine IL-
10 [245, 246]. In plasmacytoid DCs (pDCs), MyD88 sig-
naling elicited by TLR7 and TLR9 is diﬀerent from that
in myeloid DCs (mDCs). Through phosphatidylinositol 3-
kinase (PI3K), MyD88 signaling in pDCs ultimately activates
IRF7 to induce production of enormous quantities of IFN-
α [247–249]. In humans, TLR3 is predominantly expressed
in mDCs whereas TLR7 and TLR9 are exclusively expressed
in pDCs [250–255]. TLR expressions in murine DCs are not
restricted as seen in human DCs. In mice, mDCs (alter-
natively named conventional DCs, cDCs) express all TLRs
except TLR7 which is not expressed by CD8α+ mDCs [250,
256]. Indeed, murine pDCs highly express TLR7 and TLR9
along with mRNAs of all the remaining identiﬁed TLRs.Clinical and Developmental Immunology 11
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Figure 5: MyD88 signal pathway. MyD88 is the universal adaptor of all the identiﬁed TLRs except TLR3. In this ﬁgure, TLR1/TLR2 is
used to illustrate the MyD88 signal pathway. TLR1/TLR2 uses triacryl lipopeptide as the ligand to recruit MyD88 via its cytoplasmic TIR
domain. MyD88 interacts with DD to associate with IRAK4. IRAK4 then phosphorates IRAK1 and IRAK2 activates TRAF6. TRAF6 induces
the synthesis of polyubiquitin chains that links TRAF6, NEMO, IRAK1 and TAB2, 3, 4. The ubiquitination of TAB2/3/4 in association with
TAB1activates TAK1.This induces phosphorylation of IKK complex resulting in the dissociation of IκB and NF-κB. NF-κB then translocates
into nucleus to induce the gene transcription of proinﬂammatory cytokines. TAK1 also activates JNK and p38 which induce AP1 activation.
MyD88 and TRAF6 both activate IRF5 and induce proinﬂammatory cytokines. This activation is inhibited by IRF4. TRAF6 also interacts
with TRAF3 and then recruits TBK1 to activate IRF3 and IFN-β production. TRAF3 alternatively induces the anti-inﬂammatory cytokine
IL-10.
TLR3 is preferentially expressed in CD8α+ mDCs and pos-
sibly not expressed in pDCs [250, 256]. Therefore, eﬀective
antitumor immunity elicited by CpG DNA in mouse is not
seen in humans [257].
TRIF is the sole adaptor of TLR3 and the adjunctive
adaptor of TLR4. After sensing dsRNA, the TIR domain
of TLR3 associates TRIF TIR, then TRIF interacts with
receptor-interacting protein 1 (RIP1) through the RIP
homotypic interaction motif (RHIM) present in both pro-
teins (Figure 6). TRAF6 is also recruited to the N-terminal
domain of TRIF followed by polyubiquitination of RIP1.
Peli1, a member of Pellino family of RING-like domain-
containingE3ubiquitinligases,alsoparticipatesinRIP1pol-
yubiquitination along with TRAF6 [258]. The polyubiquiti-
natedRIP1recruitstheubiquitinreceptorproteinsTAB2and
TAB3, which in turn activate TAK1 [259]. TAK1 then phos-
phorylates IKKα and IKKβ leading to degradation of IκB
which results in the translocation of NF-κB to cell nucleus
to stimulate proinﬂammatory cytokine production [260].
Similar to MyD88 signaling, TAK1 activates AP1 through
JNK and p38. TRIF also associates its adaptor protein NF-
κB activating kinase- (NAK-) associated protein 1 (NAP1)
to activate TBK1 and IKKε resulting in the phosphorylation
and nuclear translocation of IRF3, inducing the expression
of IFN-β [261]. TRAF3 combines with the TBK1/IKKε
complex and is also involved in the TRIF-mediated IRF3
activation [245]. It is a unique signal pathway of TRIF that
interacts with Fas-associated cell death domain (FADD)
proteinthroughRIP1whichinturnactivatesprocaspase-8to
initiate cell apoptosis [262, 263]. Recently, a TIR-less splice
variant of TRIF (designated as TRIS) was found capable of
activating IRF3 through the interaction with TBK1 and/or
activating NF-κBv i aR I P 1[ 264]. TLR3 itself is also involved
in signaling, for example, the phosphorylation of Tyr759 and
Tyr858 in the TLR3 TIR domain. Phosphorylated Tyr759
recruits PI3K to activate kinase Akt which in turn activates
IRF3 in nucleus [265]. Additionally, the phosphorylation of
Tyr759 and Tyr858 induces degradation of IκB to release and
partially activate NF-κB by phosphorylation [266]. Tyrosine
kinase c-Src also involves Akt activation [267].12 Clinical and Developmental Immunology
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Figure 6: TRIF signal pathway. In TLR1-TLR13, TRIF is the sole adaptor of TLR3 and also an adjunct adaptor of TLR4. Here, the TLR3-
TRIF signal is illustrated as an example of TRIF pathway. dsRNA that is internalized in endosome binds to TLR3, which possesses two
dsRNA binding sites near the N-terminus and C-terminus, respectively. When combined with dsRNA, a sole dsRNA molecule associates
two TLR3 molecules through four dsRNA binding sites in an “m” shape. TLR3 TIR domain combines with the TIR domain of TRIF. The
interaction of TRIF with RIP1 or TRAF6 and Peli1 results in polyubiquitination of RIP1, the latter binds ubiquitin receptors TAB2 and TAB3
which activates TAK1. Activated TAK1 induces phosphorylation of IKK complex composed of IKKα and IKKβ and NEMO. This results
in the degradation of IκB which ultimately causes the nuclear translocation of NF-κB to activate the speciﬁc gene promoter A20. TAK1
also interacts with JNK and p38 to activate c-JUN and ATF2. This results in the activation of the AP-1 transcription factors family. TRIF
alsoactivatesTBK1andIKKε throughNAP1inducingphosphorylationandnucleartranslocationofIRF3culminatinginIFN-β production.
TRAF3bindswiththeTBK1/IKKεcomplexinducingIRF3activation.CombinationofTRIFresultsinphosphorylationofTyr759andTyr858
in the TLR3 TIR domain which subsequently induces the phosphorylation and degradation of IκB leading to NF-κB release. Phosphorylated
Tyr759 recruits PI3K and phosphorylates kinase Akt and activates nucleic IRF3. Tyrosine kinase c-Src also plays a role in Akt activation. The
unique signaling of TRIF is that it interacts with FADD through RIP1 and activates procaspase-8 to initiate cell apoptosis.
4. Effects of TLR Activation on T Lymphocyte
Subsets Differentiation
4.1. TLR Signals Aﬀect Thymocytes Diﬀerentiation. Various
viral infections through TLR interaction can induce type I
IFN production. TLR3 recognizes ssRNA virus (West Nile
virus), dsRNA virus (reovirus), respiratory syncytial virus,
mouse cytomegalovirus (MCMV); TLR7 recognizes ssRNA
viruses (vesicular stomatitis virus, inﬂuenza virus); TLR8
recognizes ssRNA from RNA virus; TLR9 recognizes dsDNA
viruses (Herpes simplex virus, MCMV), CpG motifs from
bacteria and viruses [268, 269]. Treatment of newborn mice
with an active IFN-α2/α1 hybrid molecule reduced thymus
cellularity by 85%. Phenotypic analysis revealed that the
quantity of CD44+CD25− DN1 cells increased while that
of CD44−CD25− DN4 cells decreased suggesting that the
IFN-α2/α1 inhibition of T-cell development begins at an
early progenitor stage [270]. There are deleterious eﬀects
of IFN-α on T-cell development mediated by upregulation
of cyclin-dependent kinase inhibitor p27Kip1 [271]. The
TLR3 ligand polyinosinic-polycytidylic acid (poly(I:C)) and
TLR7 ligand loxoribine are capable of inducing type I
IFN expression resulting in a decrease in CD44−CD25+
DN3 population [272]. Poly(I:C) can block the DN1-
DN2 transition, diminish the DN3-DN4 cell proliferation,
promote apoptosis of DP thymocytes, which culminate in a
reduced thymic output [273]. As poly(I:C) can activate the
cytoplasmic helicases RIG-I and melanoma diﬀerentiation-
associated gene 5 (MDA-5) pathways [260], the inhibitory
eﬀects of poly(I:C) on T-cell development may be not
solely mediated by TLR3. Activation of MDA-5 causes a
reduction in thymus size while TLR9 ligand CpG DNA and
TLR4ligandlipopolysaccharide(LPS)didnotreducethymus
size [274]. Upon stimulation by LPS, the gene expression
of downstream signals of TLR3 and TLR4, that is, TRIF
signal, is the most diﬀerentially aﬀected pathway in murineClinical and Developmental Immunology 13
thymocytes, suggesting a direct inﬂuence of altered TLR
signaling on thymus involution [275].
4.2. Eﬀects on T-Cell Diﬀerentiation through TLR Activation
inAPC. TLRsactivationhasbeenshowntobridgetheinnate
and adaptive immunity [212, 276–278]. Beside its expression
in professional APCs such as DCs and macrophages [276],
TLRs can be expressed in T cells [254, 279, 280] and serve
as co-stimulatory signals in T-cell activation [268, 277, 278,
281]. Traditionally, activation of TLRs in APCs would lead
to the production of IFN-α, proinﬂammatory cytokines such
as TNF-α, IL-1 and IL-6, and the cytokines IL-12 and IL-
18 that instruct Th1 to diﬀerentiate, whereas an increased
Th2 response was observed in MyD88 deﬁcient mice with
impaired TLRs signaling [282–284]. The IL-12 and IL-23
secretions of DCs induced by TLRs activation are enhanced
by chemokine CCL17 in an autocrine manner. The produc-
tions of these cytokines are signiﬁcantly reduced in CCL17-
deﬁcient DCs [285]. It has been demonstrated that the dose
of antigen plays an important role in directing Th1/Th2
diﬀerentiation driving by DCs. A lower concentration of
ovalbumin (OVA) peptide (1 and 10ng/mL) induced Th2
commitment while higher concentrations (1μg/mL and
100ng/mL) failed to elicit Th2 development. Stimulation
of CD4+ T cells with DCs along with TLR2 or TLR9
agonists in the presence of the 10ng/mL of OVA peptide, the
optimal antigen concentration for Th2 development resulted
in suppression of IL-4 production and Th2 development.
This suggests that TLR-activated DCs can block Th2 lineage
commitment independent of antigen dosage [286]. A lower
dose of LPS (0.1μg), through TLR4 signaling, induced
a Th2 response to inhaled antigens in a murine allergic
sensitization model. In contrast, high doses of LPS (100μg)
w i t ha n t i g e nr e s u l t e di naT h 1r e s p o n s e[ 287]. However,
repeated administration of TLR2 ligand Pam3CSK4 or TLR4
ligand LPS leads to tolerance of TLR2 [288] or TLR4
[289] with reduced cytokine release and expression of
IRAK-1 and IRAK-4 proteins [288]. Additionally, activation
of TLR4 resulted in a MyD88-dependent Th17 response in
memory CD4+ T cells in the absence of TRIF molecule
[284]. Activation of DCs via TLR2-MyD88 also induced Th1
and Th17 cell diﬀerentiation [290]. Still, signaling of TLR2
can inhibit DCs to produce IL-12p70 by dampening the
type 1 IFN ampliﬁcation loop. This signaling also drives
the immune response induced by synergistic combination of
TLR4 and TLR7/8 agonists (both are potent inducers of Th1
responses) toward Th2 and Th17 responses in the naive and
memory T-cell subpopulations [291]. Murine DCs activated
byLPSorCpGoligodeoxynucleotide (ODN)overcameTreg-
mediated suppression by inducing IL-6 signals [292]. IL-6
also mediates the downregulation of Foxp3 expression in T
cells induced by TLR7-activated DCs [293]. However, activa-
tion of TLR7 by resiquimod in OVA-induced experimental
model of murine allergic asthma resulted in expansion of
TregcellthroughaTGF-β-dependentpathway[294].Thus,it
seems that T-cell subsets activated by TLR signals from APCs
vary depending on the type and the status of APC involved,
the cytokine milieu, as well as the amount of the antigen
present [295–297].
On the other hand, a recent report indicated that signals
from Th cells can govern the formation and function of spe-
cialized DC subsets, for example, Th1 and Th17 cells cause
monocytes diﬀerentiation into Th1- or Th17-promoting
DC subsets in psoriasis lesion, and Th2 cells induce the
production of Th2-promoting DC subset in acute atopic
dermatitis [298]. The phenotype of these polarized DC
subsets cannot be altered even after subsequent stimulation
of TLR ligands. With stimulation by ligands of TLR1-TLR9,
the quantities of cytokine secreted by the specialized DC
subsetwerechangedbuttheoverallcytokinesecretionproﬁle
remained the same [298]. The TLR signaling in DCs is
negativelyregulatedbyadapterscontainingimmunoreceptor
tyrosine-based activation motif (ITAM) sequences to sup-
press activation of DCs [299], for example, DNAX-activating
protein of molecular mass 12 kilodaltons (DAP12) in mDCs
[300] and Fc receptors for IgG in pDCs [301]. The triggering
receptor expressed on myeloid cell-2 (TREM-2) associates
DAP12 to suppress TLR signaling in bone-marrow-derived
DCs [302]. The ligand of TREM-2 is also detected on the
surface of these DCs. Thus, it seems that the preexisting
polarized immunity dictates that the subsequent immune
response and this polarization will not be altered even if
stimulated by PRR.
4.3. Direct Activation of TLR in CD4+ TE ﬀector Cells Induces
Costimulation. The expression and the activity of TLRs in T
cells are related to the functional status, for example, eﬀector
or memory cells and central memory or eﬀector memory
cells as well as the activation status of T cells by TCR signals
(Table 1)[ 268, 277, 303]. Murine naive T cells can express
TLR1-TLR9 although there is a considerable variation in
expression levels [303]. TLR1, TLR4 and TLR6 were among
those maximally expressed in CD4+ and CD8+ T cells [277].
Although naive human CD4+ T cells express signiﬁcant
levels of intracellular TLR2 and TLR4 protein, cell surface
expression of TLR2 and TLR4 was found only in activated
CD4+ T cells [281]. Cell surface expression of TLR2 in
CD4+CD45RO+ (memory) T cells is signiﬁcantly higher
than that of CD4+CD45RA+ (naive) T cells. However, TLR2
expression by naive T cells can be signiﬁcantly increased
by anti-CD3 activating TCR. This is enhanced by TLR2
ligand. An activation marker, HLA-DR antigen, was found
coexpressed with TLR2 in parallel suggesting that TLR2
expression is associated with T-cell activation [281]. Similar
results were also obtained in CD8+ T cells with transcript
copies of TLR2 mRNA in CTLs 7–10 times higher than
that in naive CD8+ T cells [304]. However, TLR expression
in T cells is controversial. When poly(I:C) and CpG DNA
were added to murine CD4+ T-cell cultures that were TCR
activated by anti-CD3 antibody, TLR3 and TLR9 expression
was upregulated with enhanced survival. By contrast, levels
of TLR2, TLR4 were undetectable when peptidoglycan and
LPS were used [305]. Activated murine CD4+CD25− eﬀector
T cells can functionally express TLR2 [306]. The discrepancy
may be attributed in part to the diﬀerent protocols used
for T-cell puriﬁcation and the diﬀerent ligands used for
TLR activation. A study compared the diﬀerences in purity,
activation requirements, speciﬁcally, the response to TLR14 Clinical and Developmental Immunology
Table 1: TLR expression and direct eﬀects on T cells [268, 277, 278, 329, 333].
TLR Location Typical ligand
Expression in T-cell subsets
Direct eﬀect on T cells
naive Activated/Memory iTreg
TLR1 Cell surface Triacryl lipopeptide ± ++ + Increased eﬀector T-cell proliferation and survival;
abrogate the suppressive function of Treg cells
TLR2 Cell surface Peptidoglycan ± ++ +
Increased cell proliferation and survival; promote
cytotoxic activity of CTL; generate eﬃcient memory T
cells; augment Treg cell proliferation with temporal loss
of suppression
TLR3 Endosome dsRNA + ++ − Promote activated CD4+ T-cell survival
TLR4 Cell surface Lipopolysaccharide ± ++ + Induce Treg cell activation; enhance the suppressive
function of Treg cells
TLR5 Cell surface Flagellin + + + Augment the suppressive capacity of Treg cells
TLR6 Cell surface Diacryl lipopeptide + + + Block the suppressive function of Treg cells
TLR7 Endosome ssRNA + + − Augment activation/function of T cells; block the
suppressive function of Treg cells
TLR8 Endosome ssRNA + + + Augment activation/function of T cells; block the
suppressive function of Treg cells
TLR9 Endosome CpG DNA + ++ − Promote activated CD4+ T-cell survival; inhibit Treg
cell suppression
++: enhanced expression; +: normal expression; ±:w e a ko rl o we x p r e s s i o n ;−: expression not detectable.
ligands of human CD4+ T cells isolated by immunomag-
netic cell sorting (IMACS-CD4+)o rb yI M A C Sf o l l o w e d
by ﬂuorescence-activated cell sorting (FACS, IMACS/FACS-
CD4+)[ 307]. It showed that the IMACS/FACS-CD4+ T
cells were highly puriﬁed (99.7%) and when stimulated by
TLR4 ligand LPS, in the absence of TCR activation by anti-
CD3 and costimulation from anti-CD28 did not elicit a
response. On the other hand, a less pure sample of IMACS-
CD4+ T cells (92.5%) showed IL-2 and IFN-γ secretion
responding to anti-CD3 without anti-CD28. Stimulation
with anti-CD3, anti-CD28, and LPS signiﬁcantly increased
proliferation and cytokine production of IMACS-CD4+ but
not IMACS/FACS-CD4+ T cells. The expression of TLR4
was also signiﬁcantly higher in IMACS-CD4+ cells than
in IMACS/FACS-CD4+ cells. This diﬀerence is likely to be
the result of contaminating accessory cells in IMACS-CD4+
population [307]. Another report using LPS derived from
Salmonella enteritidis, Salmonella minnesota and Salmonella
typhimurium demonstrated that only LPS from Salmonella
typhimurium can induce proliferation and IFN-γ secretion
in murine CD4+ T cells [306].
T L R se x p r e s s e di nTc e l l sh a v eb e e ns u g g e s t e dt oa c ta s
co-stimulatory molecules involved in T-cell activation [268,
277]. Application of Pam3CysSK4, the ligand of TLR1/TLR2
complex, in activated TCR transgenic mice CD8+ Tc e l l s
resulted in increased cell proliferation and survival. This
was associated with a sustained CD25 expression and an
enhanced expression of Bcl-xL, an antiapoptotic molecule.
TLR2 engagement also enhances production of IFN-γ and
granzyme B, promotes cytotoxic activity of antigen-activated
CD8+ T cells, reduces the activation requirements for co-
stimulatory signals from APC and TCR signal strength, and
generates eﬃcient memory T cells in response to a weak TCR
signal [308, 309]. TLR2 engagement on CD8+ memory T
cells is also involved in the direct control of memory cell pro-
liferation and IFN-γ production [310]. The co-stimulatory
role of TLR2 ligation on CD8+ T cell is believed to be due to
the intrinsic TLR2-MyD88 signaling and PI3K-Akt pathway
activation in CD8+ T cells [308, 311]. PI3K signal activated
by MyD88 adaptor is indispensable to the costimulation of
CD4+ T cells by TLR9 ligand CpG ODN [312]. Costimula-
tion by poly(I:C) of naive CD4+ T cells through TLR3 in the
presence of anti-CD3 and anti-CD28 can induce synthesis
of IL-17A and IL-21, this being dependent on activation of
the NF-κB pathway. IL-17A and IL-21 cause naive CD4+ T-
celldiﬀerentiationtowardanIL-21phenotype.Thesecellsdo
not have the transcription factors T-bet, GATA-3 and ROR-c
that represent the induction of Th1, Th2 and Th17 subsets,
respectively [313] and consequently such cells are absent.
TLR ligands can act directly on highly puriﬁed T cells in the
absence of CD28 engagement [303] but is unable to induce
functionalresponsesinnaiveTcellswithoutconcurrentTCR
stimulation [308]. Therefore, TLR-induced signals in T cells
are strictly co-stimulatory [303]( Figure 7).
4.4. Eﬀects of Direct Activation of TLR on Treg Cells.
TLR2 agonist Pam3Cys acts directly on puriﬁed Treg cells
resulting in an augmented Treg cells proliferation. This is
accompanied by a temporal loss of the suppressive Treg
phenotype in the presence of TCR stimulation [314]a n da
transient suppression of Foxp3 expression [306]. The eﬀects
of a reversal of suppression on responder T cells by human
CD4+CD25+Foxp3+ Tregcellsinﬂuenced bythe TLR2ligand
were Akt being phosphorylated and p27Kip1 (The cyclin-
dependentkinaseinhibitorwhichishighlyexpressedinTregs
and capable of arresting cell-cycle in the G1 phase, and can
be reduced by IL-2) being downregulated. There was no
alteration in Foxp3 expression [315]. On the other hand,Clinical and Developmental Immunology 15
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engagement of TLR2 resulted in human CD8+CD25+Foxp3+
Treg cells expansion that directly suppressed CD4+ T-
cells proliferation by cell-contact inhibition and triggered
CD4+CD45RO+ memoryT-cellapoptosis inhibiting allergen
induced Th2 immune responses [316]. Treg cells are able
to regain their suppressive property in the presence of IL-2
oncetheTLR2ligandisremoved[306,314].AlthoughTLR2-
stimulated Treg cells readily lost their ability to suppress pro-
liferation of eﬀector T cells, cytokine production by eﬀector
T cells was still repressed. This suggests that the activity of
Treg cells was cytokines independent [317]. Treg and Th17
cells are considered divergent and mutually inhibitory. It
has been reported that when naive CD4+ T cells were stim-
ulated with TLR2 agonists Th17 diﬀerentiation in vitro
and Th17 cytokine production occurred [318]. Thus, the
reduced suppressive function of Treg cells induced by TLR2
stimulation may be a result of imbalanced phenotype and
function between Treg and Th17 [315]. The suppression
seen in both CD4+CD25hiFoxp3lowCD45RA+ naive and
CD4+CD25hiFoxp3hiCD45RA− memory or eﬀector Treg
cells on CD4+CD25−Foxp3−CD45RA+ naive responder T
cells can be reversed by activated TLR1/2. This is accompa-
niedbyincreasedproductionofIL-6andIL-17,upregulation
of ROR-c and downregulation of Foxp3 expression [319].
Pam3Cys-mediated reduction of Treg suppressive function
can be abrogated by neutralization of IL-6 or IL-17 [319]. All
together, in a bacterial infection, the TLR2 ligand augments
the functional activities and the clonal expansion of eﬀector
T cells as well as temporarily attenuating the suppressive
function of Treg cells against the invading pathogen. The
TLR2 signal also promotes the expansion of Treg cells that
have reduced suppressive function. As the TLR9 ligand
can reprogram Treg population toward Th17 diﬀerentiation
[320, 321], it is conceivable that TLR2 may play a role in Treg
cell reprogramming. The proinﬂammatory cytokines IL-6
and IL-1β are crucial reprogramming cytokines of Treg cells
toward Th17 diﬀerentiation [322, 323]. When a pathogen
is eliminated, the expanded clusters of Treg cells recover
their suppressive activity preventing autoimmunity that may
resultfromoveractivatedeﬀectors(Figure 1)[303,306,324].
However, it is not known whether the changes observed in
reprogrammed Treg cells can be reversed.
Pam3CSK4, a TLR1/TLR2 ligand can induce tumor
remission in severe combined immunodeﬁciency (SCID)
mice by diminishing the suppressive function of Foxp3+ Treg
cells and enhancing the cytotoxicity of tumor-speciﬁc CTLs.
Adoptive transfer of CTLs and Treg cells pretreated with
Pam3CSK4 from wild-type mice into tumor-bearing SCID16 Clinical and Developmental Immunology
micecanrestoreantitumorimmunityinSCIDmicebyrecip-
rocal downregulation of Treg cells and upregulation of CTL
function [325]. However, treatment of CD4+CD25+ Treg
cells with intrinsic TLR2 agonist, heat shock protein (HSP)
60, before anti-CD3 activation signiﬁcantly enhanced the
suppressive ability of the Treg cells to inhibit CD4+CD25− or
CD8+ T-cell proliferation, IFN-γ and TNF-α secretion [326].
Nevertheless,thepurityofCD4+CD25+ Tregcellsusedbeing
>90% implies possible contamination of other cell types.
Not all the CD4+CD25+Foxp3+ cells from peripheral blood
activated by HSP60 are Treg cells. Activated CD4+ eﬀector T
cells can also transiently express Foxp3. It should be noted
that only cells with CD4+CD25+Foxp3+CD30+ phenotype
possess suppressive function. This induction of Treg cells by
HSP60 is enhanced by signaling via TLR4 on APCs [327].
Thus, contaminated APCs within the Treg cell population
may promote the suppressive function of Treg cells by TLR4
signaling triggered by HSP60 in APC rather than by TLR2
signaling in Treg possibly accounting for this discrepancy.
Indeed, TLR2 expression in human CD4+CD25+CD127−
Treg cells isolated from peripheral blood mononuclear cells
is not present [328].
Activation of TLR4 in CD4+CD25+ Treg cells by LPS, in
the absence of APC, can directly induce Treg cells activa-
tion. This activation involves the upregulation of activation
markers, for example, CD69, CD44, CD38, as well as B7-
1 and promotes cellular survival and proliferation [329].
TLR4 expression can be detected in peripheral human
CD4+CD25+ Treg cells. Co-culture of these Treg cells
with LPS induced activation of Treg cells with decreased
expression of Foxp3. These cells repressed neutrophils in an
IL-10- and TGF-β-dependent manner [330]. However, the
enhancement of Treg cell function by LPS was not repro-
ducedbyotherinvestigators[306,314,331].Itispossiblethat
potential contamination of commercial LPS preparations
with TLR2 ligands [314] or the presence of impurities of the
cells [332] may create discrepant results [306, 314, 331].
Application of TLR5 agonist ﬂagellin augments the sup-
pressive capacity of CD4+CD25+ T r e gc e l l sw i t he n h a n c e d
expression of Foxp3. CD4+CD25+ Treg cells can suppress
eﬀector T cells in a ratio of 1:81 and this inhibition was
increased to 1:243 with the addition of ﬂagellin [331]. TLR8
is exclusively expressed in human Treg cells, and triggering
of TLR8-MyD88-IRAK4 signaling pathway can reverse the
suppressive function of Treg cells [333]. A co-stimulatory
eﬀect of CpG DNA on CD4+CD25− eﬀector T cells is to
abrogate the suppression by Treg cells [334]. CpG DNA can
also directly act on CD4+CD25+ Treg cells to inhibit its
suppressive eﬀects [334]. Thus, the direct eﬀect of individual
TLR ligand on Treg cell is completely diﬀerent although
almost all of the TLR signals share a common pathway
(Table 1).
Treg cells’ phenotypic plasticity is seen by their expres-
sion of proinﬂammatory cytokines such as IL-17, IFN-γ,
or IL-2 under certain conditions and their reprogramming
into Th-like cells [321, 322]. Mice systemically administering
highdosesofCpGODNat50–100μg/mouseshowactivation
of naive Treg cells in the spleen to acquire potent suppres-
sor activity. This was mediated by the immunoregulatory
enzyme IDO in pDCs. When IDO was blocked, CpG
treatment stimulated pDCs to express IL-6 which in turn
reprogrammed Foxp3 lineage Tregs to express IL-17 to
become Th17-like eﬀector T cells [335, 336]. The converted
Treg cells play a helper role essential for initial priming of
CD8+ T cells to a new cross-presented antigen. This was
CD40L dependent. This process, unlike the help from con-
ventional non-Treg CD4+ cells, did not require preactivation
or prior exposure to antigen [320]. CD4+Foxp3+ Treg cells
can also be reprogrammed into Tfh lineage in mouse Peyer’s
patches under the interaction with B cells and loss of Foxp3
expression [337]. Although the reprogramming of Treg cell
has been recognized to play a critical role in the initiation of
certain innate immune responses by vaccination with a TLR
agonist adjuvant, that is, CpG ODN [320, 321, 338, 339],
the eﬀects of the activation of other TLRs besides TLR9 on
reprogramming of T cellsespecially Treg cellsarenot known.
4.5. Modulation of CD8+ T-Cell Response by TLR Activation.
Viral antigen taken up by APCs are processed into epitopes,
loaded onto MHC-I molecules and cross-presented to CD8+
Tcellselicitingananti-virusCD8+ T-cellresponse. However,
not all the potential epitopes can be equally cross-presented
to CD8+ T cells. The epitopes recognized by the most
abundant cognate T-cell populations are referred to as being
immunodominant, while those recognized by less abundant
T-cell populations are named as subdominant determinants.
Thus,theimmunodominantandsubdominantdeterminants
constitute a hierarchy (α-, β-, etc.) in an antiviral immune
response [340]. This can be altered by TLR signals. Com-
bined activation of TLR2 and TLR3 by Pam3cysk4 and
poly(I:C)attheinfectionsiteoflymphocyticchoriomeningi-
tis virus (LCMV) in mice reduced antigen uptake and cross-
presentation of an immunodominant determinant of LCMV,
NP396 and shifted it becoming a subdominant determinant.
However, administration of TLR4 ligand LPS did not induce
this shift [341]. Therefore, combined activation of multiple
TLRs could possibly induce a complex response instead of
being merely synergistic or antagonistic.
4.6. Eﬀects of TLR Activation on Peripheral T-Cell Tolerance.
The outcome of presentation by DCs depends on its acti-
vation status. DCs activated by PAMPs, for example, TLR
ligands from invading pathogen will be capable of producing
co-stimulatory molecules and proinﬂammatory cytokines
immunogenic. On the other hand, self-antigen from apop-
totic self-cells lack TLR ligands and cannot induce matu-
ration of DCs and this eventually results in tolerance [342,
343]. However, a tumor-associate antigen NY-ESO-1 was
able to induce T-cell dependent antibody response through
activation of TLR4 on DCs [344]. In addition, mature DCs
induced by distinct stimulation may function diﬀerently. A
recent study suggested that LPS matured DCs produced IL-
12 to promote CD8+ T-cell traﬃcking and inﬂammation,
whereas poly(I:C) matured DCs facilitate CD8+ T-cell inﬁl-
tration and autoimmunity in an IFN-α-dependent manner
[345]. Mesenchymal stem cells can inhibit DCs activation
induced by LPS, block DCs migration to draining lymph
node and impair its capacities to prime CD4+ T cells andClinical and Developmental Immunology 17
cross-presentation to CD8+ T cells [346]. The cross-talk
between diﬀerent DC subsets is also important. The cDCs
are indispensable for cross-presentation of cancer antigens
in eliciting potent anticancer immunity. The eﬃcacy of CpG
in anticancer immunotherapy is dependent on activation of
TLR9 in pDCs. CpG-activated pDCs induce upregulation of
co-stimulatory molecule CD80 in cDCs, thus providing an
adjuvant eﬀect in anticancer immunotherapy [347]. Some
speciﬁc DC subsets may be primarily tolerogenic even if
activated. For example, a prototypic DC subset, Langerhans
cells is found precommitted tolerogenic and unable to
translocate RelB, an NF-κB family member, to the nucleus
[348]. However, although Langerhans cells are tolerogenic to
bacteria without cell surface expression of TLRs, they can
eﬀectively sense virus and poly(I:C) to induce naive CD8+
T-cells expansion and diﬀerentiation into eﬀector cells that
are dependent on high expression of CD70 rather than
mediated by IL-12 [349]. Therefore, mature DCs are not a
homogenous population and instead a cell family with
increasing new subset member being discovered [350]. They
may function divergently depending on its activation status
[351] and otherfactorssuchas thequality of stimulation, the
communicationbetweendiﬀerentDCsubsetsandthenature
of DC subset.
Human monocytes, when cultured with Wnt5a and
subsequently stimulated by TLR ligands, can diﬀerentiate
into DCs. Enhanced production of inhibitory ligands PD-
L1 and PD-L2 rather than upregulation of CD83, HLA-DR,
CD40, CD86, CD80 and CCR7 molecules would also occur
[352]. Additionally, these cells secrete low levels of IL-12p70
and TNF-α, however, there is an increased production of
regulatory cytokine IL-10 with a reduced capacity of Th1
response. This tolerogenic DC induction by enhanced Wnt
signaling is β-catenin independent but is dependent on non-
canonical Ca2+/calmodulin-dependent protein kinase II/NF-
κBsignaling[352].Lymphnodecellsthathaveprecommitted
tolerant of self-antigen proteolipid protein, when stimulated
by both CpG ODN and this protein, divided and diﬀerenti-
ated into Th1 cell lineage. This is IL-12 dependent and these
cells are capable of inducing autoimmune encephalomyelitis
when they are transferred into naive mice [343]. The break
of this cross-tolerance depends on the speciﬁc CD4+ T-cell
help and stimulation by sole TLR ligands without the help
from CD4+ T cell is insuﬃc i e n tt oo v e r c o m et h i st o l e r a n c e
[353]. By contrast, induction of TLR signaling in T cells may
increase tolerance. T-cell intrinsic TRAF6 is essential in the
maintenance of peripheral tolerance. Deletion of TRAF6 in
T cells leads to hyperactivation of PI3K-Akt pathway and
increased resistance of T eﬀector cells to the suppression
by CD4+CD25+ Treg cells. This ﬁnally results in multiorgan
inﬂammatory disease [354]. As TRAF6 is an important
adaptor in TLR signaling, it is conceivable that activation of
TLRs expressed in T cells may involve in maintenance of T-
cell susceptibility to Treg cells via TRAF6.
Administration of TLR3 ligand poly(I:C) results in a
strong expression of PD-1 ligand (PD-L1) in all subsets of
LNSCs [56]. This may prevent the tolerized T cells in lymph
nodes regaining their eﬀector function. However, this also
implies that a virus infection in LNSCs such as FRCs would
not be eliminated hence becoming a persistent infection
[355]. Activation of TLR3 by poly(I:C) also induces upreg-
ulation of MHC-I and co-stimulatory molecules in LNSCs,
for example, CD80 and CD86 in FRCs, CD80 in LECs [56].
The net result of promoting immune response by enhanced
expression of MHC-I and co-stimulatory molecules and
promoting tolerance by augmented expression of PD-L1 is
a decreased ability of FRCs to stimulate T-cell division in the
presenceofpoly(I:C).However,thephenotypicalterationsof
these FRCs in PD-L1, MHC-I and co-stimulatory molecules
such as CD80 and CD86 are similar to the DCs being
treated by poly(I:C) [56]. The decreased stimulatory ability
oftheseFRCsisconsideredtobetheconsequenceofdeduced
production of speciﬁc antigen by FRCs [56]. Alternatively,
this varying stimulatory capacity between FRCs and DCs
may be due to the altered TLR signaling cascades in FRCs
being tolerogenic cells [356].
The discrimination of self or nonself antigen by DCs
is also TLR dependent [342]. TLRs control the TCR ligand
generation in phagosome autonomously. With the conjuga-
tion of TLR ligand, the phagocytosed antigen by DCs can be
selectively loaded on MHC-II molecules and preferentially
presentedinthecontextofcostimulation[342].Activationof
TLRs is helpful to break tolerance in immunocompromised
individuals. Blockade of CTLA4 or PD-1 in combination
of TLR9 agonist CpG ODN treatment overcomes immune
tolerance in tumor bearing mice with improved long-term
survival, increased tumor-speciﬁc eﬀector T-cell population
and decreased Treg cell levels [357].
4.7. Eﬀects of TLR Activation on Mucosal Tolerance. TLRs are
directly involved in mucosal tolerance development. PAMPs
from nonpathogenic commensal microorganisms in mucosa
are also termed microbe-associated molecular patterns
(MAMPs) [358].
TLR1, TLR2, TLR3, TLR4 and TLR5 as well as TLR9
proteins have been found expressed both in human small
intestines and colon [359]. However, their expression and
action in enterocytes are diﬀerent even within the same cell.
Activation of TLR9 through apical and basolateral surface
domains of intestinal epithelial cell (iEC) results in distinct
transcriptional responses. Basolateral activation of TLR9
induces IκBα degradation and activation of the canonical
NF-κB signal pathway. Apical TLR9 stimulation elicits a
unique response with accumulation of ubiquitinated IκBα
in cytoplasm-suppressing NF-κB activation. This results
in intracellular tolerance to subsequent TLR9 basolateral
challenge. It also blocks apical TLR2 and basolateral TLR3
or TLR5 stimulation [360]. However, apical engagement of
TLR3 or TLR5 is unable to induce tolerance to subsequent
basolateral TLR stimulation [360]. Nasal vaccination of
OVA adjuvanted by CpG overcame the nasal tolerance and
induced strong Th1 and Th2 responses through activation of
TLR9 [361]. This contrasts with the responses of commensal
bacteria that suppress Th17 response via TLR pathway to
create an immune tolerance niche for colonization. TLR2
on CD4+ T cells can be activated by polysaccharide A from18 Clinical and Developmental Immunology
Bacteroides fragilis but not other TLR2 ligands to induce
IL-10 production in the absence of APCs. Speciﬁcally,
polysaccharide A treated CD4+Foxp3+ Treg cells display
a more potent TLR2-dependent suppressive capacity than
those treated by other TLR2 ligands [362].
The mechanism of TLR in maintaining intestinal home-
ostasis is not fully understood. TLR hyporesponsiveness
to commensal microbiota has been suggested to play an
important role in keeping homeostasis in the gut. Several
mechanisms to account for this hyporesponsiveness include
downregulating TLR surface expression and upregulated
inhibitory Toll interacting protein with reduced phosphory-
lation of IRAK [363]. The hyporesponsiveness of intestinal
DCs to TLR ligand engagement appears limited to TLR4
[364]. Activation of TLR3 by poly(I:C) in iECs induced
retinoic acid early inducible-1 production breaks self-
tolerance [365]. Thus, without commensal microbiota, the
engagement of TLR in gut epithelial cells from fetal or
germ-free animals can induce an inﬂammatory response.
iECs develop TLR tolerance immediately after commensal
microbial colonization [366, 367]. It has been suggested
that microRNA-146a-mediated translational repression and
degradation of IRAK1 are responsible for the induction of
neonatal innate immune tolerance in intestinal epithelium
[368]. The activation of TLR3, TLR4, TLR5 and TLR9 in
iECs induces mitogen-activated protein kinase phosphatase-
1 (MKP-1) mediated by NF-κB signaling. MKP-1 plays an
important role in the development of tolerance to TLR
engagement [369]. Immunity to bacterial infection is tam-
pered in TLR adaptor MyD88 deﬁcient mice [370–372].
The absence of TLRs or MyD88 increased susceptibility to
DSS-induced experimental colitis [360]. Administration of
TLR ligands in these animals prevents the development of
colitis [373]. Therefore, a base level of TLR signaling from
the luminal commensal microbiota is required to maintain
intestinal homeostasis [370].
A variety of DCs have been identiﬁed in intestine [374].
pDCs play an important role in the development of oral
tolerance. Orally ingested antigen is presented to T cells in
liver by pDCs to induce T-cell anergy or lineage deletion
through a CD4+ T-cell-independent mechanism [375, 376].
TheoutputofDCsfromlaminapropriacanbeincreased20–
30 fold by oral administration of TLR7/8 ligand resiquimod
[377]. The activation of TLR in iECs also augmented
the DCs sampling of antigen through their extension into
gut lumen [86]. Stimulation of human monocyte-derived
macrophages with a Gram-positive commensal Lactobacillus
rhamnosus GG or a Gram-positive pathogenic Streptococcus
pyogenes demonstrated that both the bacteria can promote
TLR2 expression in macrophages. However, only pathogenic
bacteria are capable of augmenting IFN-α/β-dependent
TLR3 and TLR7 gene expression. Thus, it suggested that
human macrophages can discriminate the presence between
commensal and pathogenic bacteria by IFN-mediated TLR
gene regulation [378, 379]. Intestinal DCs also play a
similar discriminative role in identiﬁcation of commensal
or pathogenic agents and the subsequent decision between
tolerance and immunity in intestines [380].
5. ConclusiveandPerspectiveRemarks
T cells play a central role in the cell-mediated immunity of
the host. All subsets of T cells originate from thymocytes
in thymus where they acquire their surface TCR repertoires
and develop the primary phenotypic markers then migrate
to peripheral lymphatic organ. Upon detection of infectious
agents, T cells are activated and diﬀerentiate into eﬀector
T cells or Treg cells. TLRs are canonical members of
PRRs capable of inducing T-cell activation through cross-
presentation of APCs or directly acting on T cells. Activation
of all the identiﬁed TLRs except TLR3 results in signaling
through the MyD88-NF-κBp a t h w a y .I ti sn o tk n o w nw h y
activation of TLRs by diﬀerent ligands results in diﬀerent
outcomes although they act via a common pathway.
The lymph node is the major peripheral lymph organ
where antigen-speciﬁc responses or tolerance is triggered. As
inﬂammation is a prerequisite to induce immune responses
rather than tolerance, it is conceivable that delivery of
inﬂammatory cytokines such as IL-12, IFN-γ to the tumor
or its draining lymph node would be helpful to overcome the
immunocompromised status in some patients, for example,
in cancer patients. Thus, the immunity against cancer
which has been suppressed would be reestablished in the
cancer-bearing host. Indeed, intrinsic IL-12 is capable of
converting Foxp3+ Treg cells into IFN-γ+ Th1, IL-17+ Th17,
or Foxp3+IFN-γ+/Foxp3+IL-17+/Foxp3+IFN-γ+IL-17+ tran-
sitional cells. The transitional Foxp3+IFN-γ+ cells further
diﬀerentiate into IFN-γ+ Th1 cells but not Foxp3+ Treg cells
although they still retain their regulatory functions at this
stage [381]. Intratumoral delivery of IL-12 and granulocyte
macrophage colony-stimulating factor (GM-CSF) recruits
immunogenic DCs to tumors and later migrates to the local
draining lymph nodes. However, these cells have a short half
life and become IDO-positive tolerogenic DCs after a few
days. Interestingly, the initial recruitment and activation of
DCs as well as the subsequent switch to tolerogenic activity
are both under the inﬂuence of IFN-γ [382]. It would be of
interest to note whether the delivery of IL-12 to the lymph
node would maintain or restore these DCs immunogenic.
Current studies support the concept of reprogramming
of TLR ligands, for example, CpG ODN on Treg cells.
This raises the question of whether it might be possible
to overcome the immunosuppressive eﬀects of Treg cells,
for example, in patients with disordered immunity. Indeed
should the Th cell be reprogrammable, the roadmap of
autoimmunity therapy and/or other types of therapy would
have to be reevaluated. Some disorders of immunity requir-
ing enhanced immunosuppression can occur in the context
of liver transplantation [383], kidney transplantation [384],
or stem cell transplantation [385] to name a few examples.
Exploiting such pathways could lead to the development of
new therapeutic agents against immune disorders.
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